OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hellmann on the Utility of Minimally Invasive Surgery in Cervical Cancer

January 18th 2020

Mira Hellmann, MD, discusses the utility of minimally invasive surgery in cervical cancer.

Utility of Trapelo to Increase Molecular Testing Rates

January 18th 2020

Lori Brisbin, discusses Trapelo, a new automated tool to help increase the number of patients who receive molecular testing as a precision medicine effort.

Dr. Hudson on Repeat Molecular Testing in Relapsed/Refractory NSCLC

January 18th 2020

Kathryn E. Hudson, MD, discusses performing repeat biopsies on patients with relapsed/refractory non–small cell lung cancer.

Dr. Burris on Ongoing Research With ADCs in TNBC

January 18th 2020

Howard A. "Skip" Burris, III, MD, FASCO, FACP, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses ongoing research with antibody-drug conjugates (ADCs) in triple-negative breast cancer.

Dr. Garcia on Research With the Combination of Navitoclax/Ruxolitinib in Myelofibrosis

January 18th 2020

Jacqueline S. Garcia, MD, instructor in Medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses research with the combination of navitoclax and ruxolitinib (Jakafi) in patients with myelofibrosis.

Dr. Ribeiro on Criteria for Determining Borderline Resectability in Pancreatic Cancer

January 18th 2020

Afonso Ribeiro, MD, medical director of Advanced Endoscopy and Gastroenterology at Memorial Healthcare System, discusses the criteria that can be used to determine whether a patient with pancreatic cancer is borderline resectable.

Dr. Yorio on Searching for Biomarkers in Metastatic Lung Cancer

January 18th 2020

Jeff Yorio, MD, discusses the search for biomarkers and using next-generation sequencing in metastatic lung cancer.

Dr. Munshi on the Antitumor Effect of NKTR-255 in Patients With Myeloma

January 17th 2020

Nikhil C. Munshi, MD, discusses the antitumor effect of NKTR-255 in patients with multiple myeloma.

Dr. Bryce on Next-Generation Radiopharmaceuticals in Prostate Cancer

January 17th 2020

Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the use of next-generation radiopharmaceuticals in prostate cancer.

Dr. Hurvitz on the Evolution of Treatment in Metastatic HER2+ Breast Cancer

January 17th 2020

Sara A. Hurvitz, MD, associate professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA) medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director of the Santa Monica-UCLA Outpatient Oncology Practices, and director, Breast Cancer Clinical Trials Program, UCLA, discusses the evolution of treatment in metastatic HER2-positive breast cancer.

Dr. Robson on the Application of Precision Medicine in Breast Cancer

January 17th 2020

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses the application of precision medicine in breast cancer.

Dr. Tauer on the Expansion of Subtyping in Breast Cancer

January 17th 2020

Kurt W. Tauer, MD, FACP, discusses the expansion of subtyping in breast cancer.

Dr. Wang on Precision Medicine in MCL

January 17th 2020

Michael Wang, MD, discusses the move towards precision medicine in mantle cell lymphoma.

Dr. Mesa on the FDA Approval of Fedratinib in Myelofibrosis

January 17th 2020

Ruben Mesa, MD, discusses theapproval of a second JAK inhibitor, fedratinib, to join ruxolitinib as a treatment option for patients with myelofibrosis.

Dr. Brown on the Success of Blinatumomab in the AALL 1331 Trial

January 17th 2020

Patrick Brown, MD, discusses the encouraging results of blinatumomab (Blincyto) in the AALL1331 trial.

Dr. Schlumbrecht on Treatment in Uterine Leiomyosarcoma

January 17th 2020

Matthew P. Schlumbrecht, MD, discusses the treatment of women with uterine leiomyosarcoma.

Dr. Ferraro on the Use of Molecular Profiling in Pancreatic Cancer

January 17th 2020

Pablo Ferraro, MD, discusses the use of molecular profiling in pancreatic cancer.

Dr. Koff on Systemic Therapy Options in Follicular Lymphoma

January 17th 2020

Jean L. Koff, MD, MS, discusses systemic therapies in follicular lymphoma.

Dr. Fakhri on Tumor Lysis Syndrome Associated With Venetoclax/Obinutuzumab in CLL

January 16th 2020

Bita Fakhri, MD, MPH, discusses concern over the tumor lysis syndrome that occurred in the CLL14 trial that looked at patients with previously untreated chronic lymphocytic leukemia.

Dr. Chaudhry on Novel Treatment Regimens in Relapsed/Refractory Multiple Myeloma

January 16th 2020

Maria Chaudhry, MBBS, a hematologist at The Ohio State University Comprehensive Cancer Center—James, discusses novel treatment regimens in relapsed/refractory multiple myeloma.